Effective anti-Alzheimer Aβ therapy involves depletion of specific Aβ oligomer subtypes
暂无分享,去创建一个
C. Alberini | N. Relkin | Akinobu Suzuki | W. Klein | M. Ehrlich | S. Gandy | C. Glabe | A. Hatami | E. Knight | SoongHo Kim | J. Kottwitz | R. Albay | A. Lublin | P. Szabo | J. Steele
[1] B. Solomon,et al. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[2] B. Solomon,et al. Disaggregation of Alzheimer β-amyloid by site-directed mAb , 1997 .
[3] H. Möller,et al. Human antibodies against amyloid β peptide: A potential treatment for Alzheimer's disease , 2002 .
[4] R. Wetzel,et al. Conformational Abs recognizing a generic amyloid fibril epitope , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[5] N. Relkin,et al. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals , 2002, Experimental Gerontology.
[6] Carl W. Cotman,et al. Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.
[7] Ronald Wetzel,et al. Seeding Specificity in Amyloid Growth Induced by Heterologous Fibrils* , 2004, Journal of Biological Chemistry.
[8] P. Keller,et al. Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. , 2005, Journal of neurochemistry.
[9] P. Keller,et al. Globular amyloid β‐peptide1−42 oligomer − a homogenous and stable neuropathological protein in Alzheimer's disease , 2005 .
[10] B. Solomon,et al. Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptide. , 2006, Journal of neuroscience research.
[11] Mark Bowlby,et al. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[12] B. Solomon,et al. Intravenous immunoglobulin enhances the clearance of fibrillar amyloid‐β peptide , 2006 .
[13] E. Bigio,et al. Monoclonal antibodies that target pathological assemblies of Aβ , 2007, Journal of neurochemistry.
[14] M. Ehrlich,et al. Alzheimer’s presenilin 1 modulates sorting of APP and its carboxyl‐terminal fragments in cerebral neurons in vivo , 2007, Journal of neurochemistry.
[15] P4-351: Effects of uninterrrupted intravenous immunoglobulin treatment of Alzheimer's disease for nine months , 2008, Alzheimer's & Dementia.
[16] N. Relkin,et al. Natural human antibodies to amyloid beta peptide. , 2008, Autoimmunity reviews.
[17] Jakub Hort,et al. Spatial navigation testing discriminates two types of amnestic mild cognitive impairment , 2009, Behavioural Brain Research.
[18] N. Relkin,et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease , 2009, Neurobiology of Aging.
[19] C. Glabe,et al. Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction , 2009, Neurobiology of Disease.
[20] L. Breydo,et al. Fibrillar Oligomers Nucleate the Oligomerization of Monomeric Amyloid β but Do Not Seed Fibril Formation* , 2009, The Journal of Biological Chemistry.
[21] M. Balasubramaniam,et al. Antibody concentrations to Abeta1-42 monomer and soluble oligomers in untreated and antibody-antigen-dissociated intravenous immunoglobulin preparations. , 2010, International immunopharmacology.
[22] H. Tanila,et al. Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease , 2010, Journal of Neuroinflammation.
[23] N. Relkin,et al. Measurement of anti-beta amyloid antibodies in human blood , 2010, Journal of Neuroimmunology.
[24] T. Abel,et al. Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid‐β oligomers , 2010, Annals of neurology.
[25] W. Oertel,et al. Naturally Occurring Autoantibodies against β-Amyloid: Investigating Their Role in Transgenic Animal and In Vitro Models of Alzheimer's Disease , 2011, The Journal of Neuroscience.
[26] A. Wall,et al. Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers , 2012, Neurology.
[27] S. Gandy. Lifelong management of amyloid-beta metabolism to prevent Alzheimer's disease. , 2012, The New England journal of medicine.
[28] Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer’s disease , 2012, Journal of Neuroinflammation.
[29] S. Barnum,et al. IVIG immunotherapy protects against synaptic dysfunction in Alzheimer's disease through complement anaphylatoxin C5a-mediated AMPA-CREB-C/EBP signaling pathway. , 2013, Molecular immunology.
[30] C. Holmes. Intravenous immunoglobulin for Alzheimer's disease , 2013, The Lancet Neurology.
[31] G. Petsko,et al. Latrepirdine improves cognition and arrests progression of neuropathology in an Alzheimer's mouse model , 2013, Molecular Psychiatry.
[32] F. Calon,et al. IVIg protects the 3xTg-AD mouse model of Alzheimer’s disease from memory deficit and Aβ pathology , 2014, Journal of Neuroinflammation.
[33] N. Relkin. Clinical Trials of Intravenous Immunoglobulin for Alzheimer’s Disease , 2014, Journal of Clinical Immunology.
[34] S. Allan,et al. High-fat diet-induced memory impairment in triple-transgenic Alzheimer's disease (3xTgAD) mice is independent of changes in amyloid and tau pathology , 2014, Neurobiology of Aging.
[35] S. Gandy,et al. Immunomodulation and AD – Down But Not Out , 2014, Journal of Clinical Immunology.
[36] C. Glabe,et al. Monoclonal Antibodies against Aβ42 Fibrils Distinguish Multiple Aggregation State Polymorphisms in Vitro and in Alzheimer Disease Brain* , 2014, The Journal of Biological Chemistry.
[37] M. Ehrlich,et al. Proneurogenic Group II mGluR antagonist improves learning and reduces anxiety in Alzheimer Aβ oligomer mouse , 2014, Molecular Psychiatry.
[38] K. Zahs,et al. Quaternary Structure Defines a Large Class of Amyloid-β Oligomers Neutralized by Sequestration. , 2015, Cell reports.
[39] D. Lockhart,et al. Evidence that small molecule enhancement of β-hexosaminidase activity corrects the behavioral phenotype in Dutch APPE693Q mice through reduction of ganglioside-bound Aβ , 2014, Molecular Psychiatry.
[40] M. Portero-Otín,et al. Neuroinflammatory Signals in Alzheimer Disease and APP/PS1 Transgenic Mice: Correlations With Plaques, Tangles, and Oligomeric Species , 2015, Journal of neuropathology and experimental neurology.
[41] M. Sano,et al. Alzheimer disease: Solanezumab—prospects for meaningful interventions in AD? , 2015, Nature Reviews Neurology.
[42] Huadong Zhou,et al. An N-terminal antibody promotes the transformation of amyloid fibrils into oligomers and enhances the neurotoxicity of amyloid-beta: the dust-raising effect , 2015, Journal of Neuroinflammation.
[43] J. Dudley,et al. Molecular systems evaluation of oligomerogenic APPE693Q and fibrillogenic APPKM670/671NL/PSEN1Δexon9 mouse models identifies shared features with human Alzheimer's brain molecular pathology , 2015, Molecular Psychiatry.